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ALT = Alanine transaminase  
CA = Ammon’s horn 
EAAC = EAAT3 = EAAC1 
EAAT = Excitatory amino acid transporter 
GABA = gamma amino butyric acid  
GAD = Glutamate dehydrogenase 
GAT = GABA transporter 
GLAST = Glutamate-aspartate-transporter = EAAT1 (slc1a3) 
Gln = Glutamine 
GLT-1 = Glutamate transporter = EAAT2 (slc1a2) 
Glu = Glutamate 
GLUT1 = Glucose transporter 1 (slc2a1) 
GS = Glutamine synthetase  
LDH = Lactate dehydrogenase  
ML = Molecular layer 
MTLE = Mesial temporal lobe epilepsy 
NMDA = Ionotropic glutamate receptor (N-methyl-D-aspartate) 
PAG = Phosphate-activated glutaminase  
PC = Pyruvate carboxylase  
PDH = Pyruvate dehydrogenase 
PTLE = Paradoxical temporal lobe epilepsy  
SDS = Sodium dodecyl sulfate 
SDS-PAGE = Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
SNAT = Sodium-neutral amino transporter (glutamine transporter) 
TLE = Temporal lobe epilepsy  
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GABA and glutamate transporter proteins are important in relation to epilepsy because 
they represent the mechanisms that keep the extracellular concentrations of GABA and 
dicarboxylic amino acids low. GABA and glutamate are the major inhibitory and 
excitatory neurotransmitters, respectively, in the brain. Consequently, these transporters 
are major players in enabling the brain to balance inhibition and excitation. In fact, by 
microdialysis it has been reported changes in extracellular glutamate and GABA levels 
prior to and during seizures, and it has been postulated that changes in the expression or 
function of glutamate and GABA transporters may be the cause of the extracellular 
glutamate excess. Papers 1 and 2 investigate the expression and distribution of GABA 
transporters (GAT1 and GAT3) and glutamate transporters (GLAST and GLT-1) in the 
hippocampus from humans with temporal lobe epilepsy (TLE). Epilepsy comprises a 
heterogeneous group of disorders reflecting underlying brain dysfunction. Temporal lobe 
epilepsy (TLE) is one of the most common chronic seizure disorders and is the most 
intensely studied subtype. Temporal lobe epilepsy is divided into mesial temporal lobe 
epilepsy with hippocampal sclerosis (MTLE), mass-associated temporal lobe epilepsy 
(MaTLE), and paradoxical temporal lobe epilepsy (PTLE). Hippocampal sclerosis is 
believed to play a key role in the increased extracellular glutamate concentration and 
generation of seizures in MTLE. However, it is not known precisely which cell 
populations, when lost due to sclerosis, cause the network imbalance. As shown in the 
present thesis, there was no significant overall change in the expression of the main 
GABA transporters GAT1 and GAT3, but immunohistochemical staining showed 
regional differences in GAT1 immunoreactivity within the hippocampus. Similarly, the 
main glutamate transporters, GLAST and GLT-1, showed no overall significant 
difference in the expression between the non-MTLE and MTLE hippocampi in Paper 2. 
However, there was a difference in the pattern of immunolabeling for GLAST and GLT-
1. This study does not support the role of glutamate transporters as a cause of elevated 
levels of extracellular glutamate in the epileptogenic hippocampi, but undetected changes 
in the splice variants of the transporters or unexpected antibody cross-activity may lead to 
biased or even false results (Paper 4). In Paper 3 we investigated the glutamate 
homeostasis in mice lacking the GLT-1 protein. 13C magnetic resonance spectroscopy 
(MRS) of cortical tissue from GLT-1 knockout mice was performed following 
intraperitoneal injection of 13C-labeled glucose and acetate. Metabolite levels were 
analyzed from the neocortex and cerebellum. Compared with wild-type mice, GLT-1 
knockout mice had normal levels of glutamate and glutamine in the cerebellum, but they 
exhibited decreased levels in the neocortex. The findings suggest that GLT-1 in cortical 
nerve terminals may contribute significantly to the replenishment of the pool of 
transmitter glutamate thereby short-circuiting the glutamate-glutamine cycle. In 
conclusion, we did not observe any significant overall changes in the expression of 
glutamate or GABA transporters in human sclerotic hippocampi, but did observe   
regional changes. Further, the findings suggesting that GLT-1 in nerve terminals is a 
major player that needs to be followed up when conditional knockout mice become 
available. The role of glutamate and GABA transporters in temporal lobe epilepsy 
remains elusive.  
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Approximately 50 million individuals have epilepsy worldwide. The prevalence ranges 
between 4 to 8/1,000 (Hauser et al., 1991, Svendsen et al., 2007). This statistic makes it 
one of the most common neurological disorders. During a lifespan, one of ten individuals 
will experience an epileptic seizure, and one third of these individuals will develop 
epilepsy (Engel and Pedley, 2008). A seizure is commonly referred to as a 
hyperexcitability and hypersynchrony of neuronal networks, which are intrinsically 
hyperexcitable and fire synchronously and excessively (Margineanu, 2010). The 
definition does not include any pathogenetic explanation because the question of what 
causes epilepsy and epileptic seizures is, to a large degree, still unanswered. Epilepsy is a 
heterogeneous group of disorders reflecting underlying brain dysfunction. It may be 
caused by genetic abnormalities, birth damage, prolonged febrile seizures, infections, 
stroke, or tumors. Epilepsy is defined as a chronic condition of the brain characterized by 
an enduring propensity to generate epileptic seizures and by the neurobiological, 
cognitive, psychological, and social consequences of this condition (Fisher et al., 2005). 
An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal 
and excessive neuronal activity in the brain (Fisher et al., 2005).  
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One type of focal epilepsy is temporal lobe epilepsy (TLE), in which seizures originate 
from the temporal lobe. Although there are many types of genetic and acquired forms of 
epilepsy, TLE is among the most common of the chronic seizure disorders (Hauser and 
Kurland, 1975, Engel, 2001) and is the seizure disorder that is most intensely studied. 
TLE was defined in 1985 by the International League Against Epilepsy (ILAE) as a 
condition characterized by recurrent unprovoked seizures originating from the medial or 
lateral temporal lobe. Despite a wealth of descriptive data obtained from patient histories, 
imaging studies, electroencephalographic recordings, depth recordings before and during 
surgery, and histological studies of surgical and autopsy tissues, the epileptogenic process 
remains poorly understood. It is believed that when the hippocampus is asymmetrically 
atrophic on initial MRI, the shrunken hippocampus is a likely source of epileptic seizures 
in TLE (Engel, 2001). The presence of a shrunken hippocampus is also a predictive 
indicator of the medically refractory state of the disease (Semah et al., 1998). Depth 
electrode recordings demonstrate hypersynchronous electrical activity in the 
hippocampus that is often associated with auras that can spread and cause clinical 
seizures (Engel, 2001). Because this form of epilepsy is often intractable (Chadwick, 
1990), many of these patients undergo an anteromedial temporal lobectomy with 
hippocampectomy for seizure control (Spencer et al., 1984). The condition seems to be 
medically intractable in approximately 40 % of cases, and surgical resection of the 
epileptic focus is the most efficient way to control the seizures.  
 
""##!"'
TLE is divided into three broad categories, namely, mesial temporal lobe epilepsy 
(MTLE), mass-associated temporal lobe epilepsy (MaTLE), and paradoxical temporal 
lobe epilepsy (PTLE) (de Lanerolle et al., 2003). Approximately 70 % of patients with 
TLE who undergo surgical resection are classified as having MTLE. The hallmark of 
 !
MTLE is hippocampal sclerosis, which is characterized by neuronal loss and gliosis in 
the CA1, CA3, and hilar regions and reorganization of synaptic connections (Sommer, 
1880, de Lanerolle and Lee, 2005). The sclerotic hippocampal formation is the most 
probable origin of seizures, and more than 85 % of patients become seizure-free after 
removal of the these regions (de Lanerolle et al., 2003). The clinical records of MTLE 
patients typically include an insult, such as febrile seizures, a brain trauma, or a brain 
infection that predates seizure onset by several years (Mathern et al., 1996). The 
remaining 30 % of patients with TLE who undergo surgery do not exhibit hippocampal 
sclerosis. Approximately half of these patients have a mass lesion outside the 
hippocampus, but within the temporal lobe, and are described as having mass-associated 
temporal lobe epilepsy (MaTLE) (de Lanerolle and Lee, 2005). The seizures seem to be 
generated by the mass, and the surgical outcome is dependent on the type of lesion. The 
other 50 % of patients have paradoxical temporal lobe epilepsy (PTLE) with an unknown 
etiology. For PTLE patients, the prognosis after surgery is not as good as that for patients 
with MaTLE and MTLE (de Lanerolle et al., 2003). MaTLE and PTLE are referred to as 
non-MTLE. 
 
Figure 1 
Photomicrographs of glutamate transporter 
EAAT3 (EAAC) immunoreactivity in the 
MTLE hippocampus. This low power view of 
the entire cross-section of a MTLE 
hippocampus shows the hallmarks of 
hippocampal sclerosis. The immunoreactivity 
is seen in the granule cell layer (GCL), in the 
molecular layer (ML), throughout the 
Ammon’s horn (CA4, CA3, CA2, CA1) in the 
pyramidal cells, and in the subiculum. The 
hippocampus is characterized by pronounced 
neuronal loss in the CA1, CA3, and dentate 
hilus (CA4) regions; thus, there is less 
labeling in these regions. The CA2 region and 
subiculum are spared. Only neurons are 
labeled (granule and pyramidal cells). Pyr, 
stratum pyramidale; lm, lacunosum moleculare; alv, alveus; fim, fimbra. (L.P. Bjørnsen and T. Eid, 
unpublished) 
 
Hippocampal sclerosis is thought to play a key role in the generation of seizures in 
MTLE (Mathern et al., 1997, de Lanerolle and Lee). However, the exact cell types that 
cause the network imbalance and seizure discharges are not known. There is also a lack 
of an effective drug treatment that both points to the identity of the defective component 
and corrects the network imbalance to an extent that produces symptomatic improvement 
(Sloviter, 2005). If the assumption that the hippocampus is a frequent source of seizures 
is correct, the observation that typical hippocampal sclerosis involves an extensive loss of 
dentate hilar neurons and the CA1 and CA3 pyramidal cells (Meldrum, 1994) logically 
focuses attention on surviving dentate granule cells (Tauck and Nadler, 1985, Nadler, 
2003) and subicular neurons (Cohen et al., 2002) as likely seizure generator candidates. 
One hypothesis (“epileptogenic” mossy fiber sprouting) posits that a trauma- or seizure-
induced loss of vulnerable dentate hilar neurons causes granule cells to redirect their 
axonal output to each other, resulting in a recurrent excitatory network (Tauck and 
 "
Nadler, 1985, Nadler, 2003). A second hypothesis (“inhibitory” mossy fiber sprouting) 
focuses on the post-synaptic targets of vulnerable hilar neurons, which include both 
granule cells and inhibitory neurons (Sloviter, 1992). 
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Current evidence points to a complex role of glutamate and GABA in MTLE. Glutamate 
is the major mediator of excitatory signals in the mammalian central nervous system 
(Fonnum, 1984, Danbolt, 2001), while γ-aminobutyric acid (GABA) is the most abundant 
inhibitory neurotransmitter (Zachmann et al., 1966). Glutamate is almost exclusively 
located inside cells, primarily in nerve terminals (Storm-Mathisen et al., 1992, Ottersen et 
al., 1996), and the concentration inside synaptic vesicles may be as high as 100 mmol. 
The intracellular localization is essential because glutamate is relatively inactive as long 
as it is intracellular and not able to bind to receptors on the outside of the cellular 
membrane. The amounts of glutamate in brain tissue is high (5-15 mmol per kg brain 
tissue) (Schousboe, 1981), and more than 1,000-fold higher than the concentration 
required to activate glutamate receptors. The normal concentration of glutamate in the 
extracellular fluid is low, possibly as low as 25 nM (Kugler and Schmitt, 1999, Herman 
and Jahr, 2007, Zhou and Danbolt, 2013). Glutamate homeostasis depends on the 
appropriate control of glutamate metabolism (synthesis and degradation) and transport 
(release and uptake), and it is a prerequisite for normal brain function. A prolonged 
increase in extracellular glutamate triggers the death of neurons. The mechanisms that are 
in place to maintain glutamate homeostasis are quite robust and normally serve to prevent 
a detrimental increase in glutamate concentration. The handling of glutamate in the brain 
depends on a sophisticated interplay between neurons and astrocytes (for a review, see 
(Danbolt, 2001, Zhou and Danbolt, 2013)). 
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Figure 2   
Schematic presentation of a glial neuronal metabolic interaction following the uptake of [1-13C]glucose 
(Sonnewald and McKenna, 2002). [1-13C]glucose enters glycolysis in both neurons and astrocytes to form 
one molecule of [3-13C]pyruvate, which can then be converted to [3-13C]lactate or [3-13C]alanine in the 
cytosol. Alternatively, it can enter the mitochondria and be converted to [2-13C]acetylCoA, or it can be 
converted to oxaloacetate via pyruvate carboxylase (PC), an astrocyte-specific enzyme (Shank et al., 1985). 
One-third of the acetylCoA from glucose is formed in the neuronal mitochondria (Hassel and Sonnewald, 
1995a, Qu et al., 2000a), thus, it is assumed that [1-13C]glucose metabolism is primarily neuronal. [2-
13C]acetylCoA condenses with oxaloacetate to form TCA (Kreb’s) cycle intermediates, including [2-
13C]citrate and then [4-13C]α-ketoglutarate. The 13C label can exit the TCA cycle from [4-13C]α-
ketoglutarate as [4-13C]glutamate or, alternatively, continue in the cycle. Upon release, [4-13C]glutamate is 
taken up either back into the terminals (Danbolt, 2001, Waagepetersen et al., 2005, Olstad et al., 2007) or 
into astrocytes (Schousboe and Hertz, 1981, Danbolt, 2001, Huang et al., 2004), where it can be converted 
to [4-13C]glutamine by the enzyme glutamine synthetase (GS) or to [3 or 2-13C]glutamine after passage 
through the TCA cycle. Glutamine is then released into the extracellular space by a sodium-neutral amino 
transporter in the astrocytic membrane, SNAT3 (Boulland et al., 2002, Boulland et al., 2003, Mackenzie 
and Erickson, 2004, Nissen-Meyer et al., 2011). Glutamatergic neurons can take up glutamine via the 
SNAT2 (SAT2; slc38a2) located in dendrites and cell bodies (Jenstad et al., 2009). It is currently not clear 
whether terminals have a functionally significant ability to take up glutamine (Conti and Melone, 2006). 
Neuronal mitochondria can convert glutamine back to glutamate by phosphate-activated glutaminase 
(PAG). Abbreviations: ALT: alanine transaminase; GAD: glutamate dehydrogenase; GLT-1: Glutamate 
Transporter 1 (Excitatory Amino Acid Transporter 2 – EAAT2 or slc1a2); GLAST: Glutamate Aspartate 
Transporter (Excitatory Amino Acid Transporter 1 – EAAT1 or slc1a3); Glu: glutamate; Gln: glutamine; 
GS: glutamine synthetase; LDH: lactate dehydrogenase; NMDA: ionotropic glutamate receptor (N-methyl-
D-aspartate); GLUT1: Glucose transporter 1 (slc2a1); PAG: phosphate-activated glutaminase; PC: pyruvate 
carboxylase; PDH: pyruvate dehydrogenase. (Figure is based on Bjørnsen et al., 2014)  
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GABA is a multifaceted compound, and in addition to its role as a neurotransmitter, it 
serves as an intermediate in energy metabolism and amino acid homeostasis. Neuronal 
excitability is controlled by two different inhibitory mechanisms mediated through 
synaptic and extrasynaptic GABA receptors (Rossi and Hamann, 1998, Farrant and 
Nusser, 2005). The mechanisms causing dysfunctional neurotransmitter homeostasis are 
not clear; perhaps the most pertinent question is whether the changes in neurotransmitters 
are the causes or the consequences of long-standing epilepsy. It is well known that 
glutamate is associated with seizures, as substantiated by the convulsive effects of 
glutamate agonists, the anticonvulsive effects of glutamate antagonists, and the increased 
release of glutamate during seizures (Bradford, 1995). The glutamate analogue kainate is 
widely used to induce epileptic seizures and epilepsy in animal experiments (Ben-Ari, 
1985), while another kainate derivative, the toxin domoic acid, can cause status 
epilepticus and epilepsy in humans (Teitelbaum et al., 1990, Cendes et al., 1995). 
Furthermore, several new antiepileptic drugs have been shown to act by reducing 
glutamate-mediated excitatory neurotransmission via the NMDA (felbamate) and 
AMPA/kainite (topiramate) receptors (White et al., 2007). Many drugs suppress the 
release of glutamate by enhancing the inhibitory effects of GABA (Perucca, 2005). The 
results from measurements of glutamate content in the hippocampus have been 
conflicting. Low glutamate content has been observed in both humans and animal models 
of TLE (Koyama, 1972, Peeling and Sutherland, 1993, Petroff et al., 2002b), while a 
study employing in vivo microdialysis and depth electrode EEG reported elevated 
extracellular glutamate interictally in the epileptogenic vs. non-epileptogenic human 
hippocampus (Cavus et al., 2008). 
 
In 1993, During and Spencer demonstrated an increased extracellular level of glutamate 
in the hippocampal formation in patients with MTLE prior to and during seizures using 
microdialysis (During and Spencer, 1993). The increased extracellular level of glutamate 
remained elevated for several minutes after the cessation of seizure activity, indicating a 
reduced capacity for glutamate clearance. In a study of MTLE hippocampi, the 
extracellular level of glutamate was also found to be interictally elevated, i.e., in the 
period between seizures, supporting a continuous impairment of glutamate homeostasis 
(Cavus et al., 2005). Increased release and extracellular levels of glutamate lead to 
excessive stimulation of glutamate receptors, which may cause neuronal death and may 
be a final common pathway leading to several neurological diseases (Lipton and 
Rosenberg, 1994). By inducing cell death and associated structural changes, such as the 
formation of novel synapses and aberrant connections between cells, glutamate may 
contribute to the development of the hyperexcitable network associated with MTLE. 
Intracellular recordings from slice preparations of surgical specimens show that the 
dentate granule cells are hyperexcitable in MTLE. The hyperexcitability of granule cells 
is glutamate-dependent (Williamson and Spencer, 1994) and possibly related to the 
sprouting of recurrent collaterals that is known to occur (Babb et al., 1991). The latter 
finding is in line with the idea that perturbed glutamate homeostasis could be essential 
not only for the inductions of individual seizures, but also for the generation of the 
underlying structural and functional changes in the epileptic focus.  
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As mentioned earlier, a major proportion of glutamate in the brain is contained within 
glutamatergic neurons. In MTLE, there is an extensive loss of glutamatergic pyramidal 
neurons in the hippocampal formation. However, according to studies of surgical 
specimens, there is no correlation between glutamate content and neuronal loss in the 
hippocampal formation of patients with MTLE (Petroff et al., 2002a). Some hippocampi 
with the greatest neuronal loss contain a larger amount of glutamate than hippocampi 
with moderate neuronal loss. The lack of correlation between glutamate content and cell 
loss could reflect increased glutamate content in the surviving glutamatergic neurons 
and/or in astrocytes and GABAergic neurons. 
 
A theory of an imbalance in the glutamate-to-GABA ratio causing epileptic seizures is 
supported by the fact that several drugs that suppress glutamatergic or enhance 
GABAergic action are efficient antiepileptic drugs (Petroff et al., 2002a). However, such 
drugs can also have paradoxical effects, aggravating seizures in patients with certain 
epilepsy types, suggesting that the explanation of unbalanced excitation and enhanced 
inhibition may underlie epileptic seizures (Wilson and Engel, 1993, Nusser et al., 1998). 
Specifically, it has been proposed that increased GABAergic inhibition may underlie 
epileptiform hypersynchrony (Isokawa-Akesson et al., 1989). This hypothesis is 
supported by findings of GABA-dependent spontaneous rhythmic activity in brain slices 
of the human epileptic hippocampus (Schwartzkroin and Haglund, 1986). In addition, 
GABA may be excitatory in some settings, as has been demonstrated in the subiculum (a 
region of hippocampal output) of MTLE patients, where depolarizing GABA responses 
appeared to contribute to interictal epileptiform activity (Cohen et al., 2002). 
Extracellular GABA rises during and after seizures in the epileptogenic hippocampi, with 
interictally unchanged levels compared with those in non-MTLE hippocampi (During and 
Spencer, 1993, Treiman, 2001, Pan et al., 2008). In contrast, it has been shown that 
injecting mice with 3-nitropropionic acid (3-NPA) causes seizures by selectively 
inhibiting the TCA cycle in GABAergic neurons (Hassel and Sonnewald, 1995b, Zuchora 
et al., 2001). Furthermore, measurements of GABA in tissues have been inconclusive. 
Increased, unaltered, and decreased amounts have been reported in MTLE biopsy 
material (Peeling and Sutherland, 1993, Aasly et al., 1999, Petroff et al., 2002b).  
 
 
 
 
Figure 3.  
Distribution of GABA and glutamate transporters in the around a synapse in hippocampus. Fine astrocyte 
branches (g) are found adjacent to both the glutamatergic (A and B) and GABAergic synapses (C). The 
post-synaptic densities (PSD) are seen on the two glutamatergic synapses (A and B) with typical synaptic 
asymmetry. The GABAergic synapses (C) are more symmetric and are often on dendritic trunks rather than 
spines. Glutamate and GABA transporters are indicated on the neurons and astrocytes. GLAST is selective 
for astrocytes (Lehre et al., 1995), while GLT-1 is predominantly expressed in astrocytes (Danbolt et al., 
1992). Approximately 10% of the GLT-1 is located on the hippocampal nerve terminals (Furness et al., 
2008). The glutamate transporter EAAT3 is selective for neurons and is expressed at levels that are around 
100 times lower than those of GLT-1 (Holmseth et al., 2012). Figure from (Zhou and Danbolt, 2013) 
reproduced with permission. 
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After glutamate has acted on receptors, it must be cleared from the synaptic cleft to 
ensure good signal-to-noise ratios for neurotransmission and to avoid cell damage due to 
excessive stimulation (excitotoxicity). Glutamate is transformed to glutamine by the 
glial-specific enzyme glutamine synthetase (GS) inside the astrocyte after uptake 
(Norenberg and Martinez-Hernandez, 1979, Derouiche and Frotscher, 1991). Then 
Glutamine is released from the astrocyte into the extracellular space through a system N 
glutamine transporter (SN) (Chaudhry et al., 2002). Glutamine has no effect on receptors 
and may be released with no risk of excitotoxicity. Glutamine is then converted back to 
glutamate by phosphate-activated glutaminase (PAG), which is located in the outer 
mitochondrial membranes inside the neuron (van den Berg and Garfinkel, 1971, Kvamme 
et al., 2008). Finally, glutamate enters excitatory vesicles (Fremeau et al., 2004). The 
glutamate is now recycled and again ready to be released into the synaptic cleft (Pow and 
Crook, 1996). This process is referred to as the glutamate-glutamine cycle and is 
important because it allows glutamate to be inactivated by glial cells and transported back 
to neurons in an inactive (non-toxic) form (Gjessing et al., 1972, Hamberger et al., 1983, 
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Hamberger and Nystrom, 1984). A study using 13C magnetic resonance spectroscopy of 
excised tissue from humans suggested that the accumulation and impaired clearance of 
glutamate could be due to a slowing of the glutamate-glutamine cycle (Petroff et al., 
2002a). Further supporting a functional defect in glutamate-glutamine cycling was the 
finding that the enzyme glutamine synthetase (GS), responsible for converting glutamate 
to glutamine in astrocytes, was down-regulated in sclerotic hippocampi (Eid et al., 2004a, 
van der Hel et al., 2005). It is possible that these changes in glutamate cycling may 
contribute to hyperexcitability and the propensity for chronic seizures, but the role of 
these changes in epileptogenesis and the relative contributions of astrocytes and neurons 
in impaired glutamate homeostasis are not clear. The correlation of hippocampal sclerosis 
and reduced hippocampal volume with elevated extracellular glutamate levels indicates 
that there is an impaired glutamate uptake capacity in MTLE. One possible cause of this 
impairment may be a down-regulation of glutamate transporters (Meldrum et al., 1999). 
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Glutamate is primarily taken up by astrocytes and, is rapidly converted to the non-
excitotoxic amino acid glutamine (Broman et al., 2000) by the glial-specific enzyme 
glutamine synthetase (GS) (Norenberg and Martinez-Hernandez, 1979, Derouiche and 
Frotscher, 1991). The glutamate uptake system (for a review, see: (Danbolt, 2001) and 
(Zhou and Danbolt, 2013)) consists of five different transporter proteins and represents 
the only (significant) mechanism for the removal of glutamate from the extracellular fluid 
in the brain. Five different glutamate (excitatory amino acid) transporters have been 
identified: GLAST (EAAT1; slc1a3) (Storck et al., 1992, Tanaka, 1993), GLT-1 
(EAAT2; slc1a2) (Pines et al., 1992), EAAT3 (EAAC; slc1a1) (Kanai and Hediger, 
1992), EAAT4 (slc1a6) (Fairman et al., 1995), and EAAT5 (slc1a7) (Arriza et al., 1997). 
GLAST is expressed in astrocytes, while GLT-1 is expressed in both astrocytes and 
neurons (Danbolt et al., 1992, Levy et al., 1993, Chaudhry et al., 1995, Lehre et al., 1995, 
Chen et al., 2004, Furness et al., 2008). EAAT3 is neuronal and predominantly 
postsynaptic (Rothstein et al., 1994, Holmseth et al., 2012). EAAT4 is a neuronal 
postsynaptic glutamate transporter in Purkinje cell spines (Yamada et al., 1996, Nagao et 
al., 1997, Dehnes et al., 1998), and EAAT5 is primarily expressed in the retina (Arriza et 
al., 1997). Several splice variants of the various EAATs have been reported 
(Utsunomiya-Tate et al., 1997, Meyer et al., 1998, Meyer et al., 1999, Huggett et al., 
2000, Rauen et al., 2004, Rozyczka and Engele, 2005). Although both neurons and glia 
contain glutamate transporters, it is generally accepted that more than 90 % of the 
forebrain glutamate uptake activity is mediated by GLT-1 (Danbolt et al., 1992, Haugeto 
et al., 1996, Tanaka et al., 1997) (for a review and discussion, see (Danbolt, 2001) and 
(Zhou and Danbolt, 2013)). The two main glutamate transporters, GLAST and GLT-1, 
exhibit complementary expression patterns. GLAST is preferentially expressed in the 
cerebellum, whereas GLT-1 is more prevalent in the forebrain structures (Lehre et al., 
1995). For a more detailed review, see (Zhou and Danbolt, 2013). Previously, it was 
believed that GLT-1 was expressed exclusively in astroglia in the normal central nervous 
system (Danbolt et al., 1992, Levy et al., 1993, Rothstein et al., 1994, Chaudhry et al., 
1995, Lehre et al., 1995, Schmitt et al., 1996, Ullensvang et al., 1997), with the exception 
of the retina (Rauen and Kanner, 1994, Rauen et al., 1996, Harada et al., 1998). Later 
studies show that GLT-1 is expressed in the axon terminals and spines of neurons (Chen 
 
et al., 2004, Berger et al., 2005, Furness et al., 2008, Melone et al., 2009). The splice 
variant GLT-1a is the predominant neuronal isoform and is expressed in terminals in the 
hippocampus (Furness et al., 2008) and in the somatic sensory cortex (Melone et al., 
2009). The GLT-1a protein accounts for approximately 90 % of all GLT-1 variants 
(Holmseth et al., 2009).  
 
The expression of the two major high-affinity glutamate transporter proteins, GLT-1 and 
GLAST, has been investigated in brain tissue from various seizure models and from 
patients with localization-related epilepsies. Reduced expression of glutamate 
transporters is shown to cause or be associated with seizures in animal models. A 
relationship between glutamate transporter dysfunction and epilepsy has been established 
by Tanaka and colleagues, who reported that mutant mice lacking GLT-1 had increased 
extracellular glutamate levels and developed spontaneous seizures (Tanaka et al., 1997). 
Several studies using animal models have linked glutamate transporter expression and 
epilepsy, but the results of these studies have been contradictory. The majority of studies 
showed a decrease in GLAST and GLT-1 mRNA and protein (Samuelsson et al., 2000, 
Ingram et al., 2001, Ueda et al., 2001) and an increase in EAAT3 mRNA and protein 
(Ghijsen et al., 1999, Ueda et al., 2001, Crino et al., 2002, Gorter et al., 2002) in epileptic 
animal models. Other studies demonstrated an increase in GLAST mRNA (Nonaka et al., 
1998) and a decrease in EAAT3 mRNA (Akbar et al., 1998), while Simantov et al. found 
a down-regulation of EAAT3 and a modest increase in the expression of GLT-1 in 
restricted hippocampal regions (Simantov et al., 1999). A deficiency in GLAST has also 
been shown to increase the duration of generalized seizures in amygdala-kindled rats 
(Watanabe et al., 1999).  
 
There are some studies reporting on glutamate transporters in human epileptic patients. 
Tessler and colleagues (1999) found no change in the level of mRNA or protein using in 
situ hybridization and Western blotting techniques, respectively, for GLAST and GLT-1 
in the hippocampus or the temporal cortex in temporal lobe epilepsy (TLE) patients 
compared with postmortem controls (Tessler et al., 1999). Another study found that the 
expression of the glutamate transporter GLT-1 was decreased in areas with neuronal loss 
in the epileptogenic hippocampi formation (Mathern et al., 1999, Proper et al., 2002). 
Mathern and colleagues used immunocytochemical methods coupled with neuronal 
counting and image analysis. No changes in GLAST immunoreactivity (IR) were 
observed in the hippocampi of TLE patients with hippocampal sclerosis compared with 
TLE patients without hippocampal sclerosis. Decreased GLT-1-IR in the same study was 
associated with neuronal loss, while increased EAAT3-IR was seen in areas where 
neurons were spared and a decrease was seen in areas with neuronal loss (Mathern et al., 
1999). Proper and colleagues showed a general decrease in GLAST-IR and GLT-1-IR in 
the sclerotic hippocampus compared with the non-sclerotic hippocampus or postmortem 
controls (Proper et al., 2002). This decrease was accompanied by a decrease in mRNA 
levels of both transporters. An increase in neuronal EAAT3 protein levels in the resistant 
areas (CA2 region, granule cell layer, and subiculum) in the hippocampal sclerosis group 
was also observed. Other investigators failed to detect alterations in astroglial glutamate 
transporters in human TLE or in laboratory models of seizures. For example, in patients 
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undergoing resective brain surgery for the treatment of TLE, no differences in the 
expression of GLT-1 or GLAST were found.  
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Inhibition of GABA transport increases the extracellular levels of GABA and mediates 
seizure protection (Nielsen et al., 1991); the therapeutic potential of GABA transporters 
(GAT) inhibition has been confirmed with the successful development of the GAT1 
selective drug tiagabine (Nielsen et al., 1991). An increase in GABAergic interneurons 
expressing GAT1 has previously been reported in the rat neocortex 24 hours after 
corticotropin-releasing hormone-induced seizures (Orozco-Suarez et al., 2000), and a 
transient increase in GAT3 mRNA (but not protein) expression has been described in 
amygdala-kindled rats 1 hour after the last seizure (Hirao et al., 1998). These findings 
suggest that seizure activity is associated with an upregulation of neocortical GAT 
expression. Increased GAT expression could lower extracellular GABA levels, thus 
contributing to the origin and spread of epileptic activity. Alternatively, because GABA 
transporters can function in reverse (Sihra and Nicholls, 1987, Pin and Bockaert, 1989, 
Attwell et al., 1993, Levi and Raiteri, 1993, Jaffe and Figueroa, 2001, Wu et al., 2006), 
an up-regulation of GATs following sustained neuronal activity may induce a 
compensatory increase in GABA release via a non-vesicular, transporter-mediated 
mechanism (During and Spencer, 1993, Gaspary et al., 1998, Wu et al., 2006). 
Transgenic mice that overexpress the GAT1 protein exhibit increased susceptibility to 
chemically induced seizures, although they do not display spontaneous seizure activity 
(Ma et al., 2001). Enhanced GAT1-mediated GABA transport was also associated with 
seizures in a genetically epileptic mouse strain (Fueta et al., 2003). Evidence for a down-
regulation of GAT function in the epileptic neocortex has also been reported. Cortical 
GABA uptake is reduced in different genetic mouse and rat models of epilepsy (Cordero 
et al., 1994, Cordero et al., 1994b, Sutch et al., 1999), and GAT1 mRNA expression is 
reduced in the neocortex of genetically epileptic-prone rats (Akbar et al., 1998). In a 
pilocarpine rat model of TLE, GAT1 was found to be reduced, particularly in the 
perisomatic axon terminals in the sensorimotor cortex (Silva et al., 2002). Hippocampal 
GABA transporter immunoreactivity differs in TLE patients compared with autopsy 
tissue (Mathern et al., 1999). There was an increase in GAT1 expression in the outer 
molecular layer of the hippocampal dentate and increased astrocytic GAT3 in the hilus 
and Ammon’s horn. In contrast, another study showed that GAT1 was reduced and 
abnormally distributed in the neocortex of patients with TLE and focal dysplasia 
(Spreafico et al., 2000). The substantial reduction in perisomatic terminals expressing 
GAT1 reported in the epileptic neocortex (Silva et al., 2002) and hippocampus (Sayin et 
al., 2003, Arellano et al., 2004) is in line with the notions that the loss of the GABAergic 
cells innervating the soma and initial axon segment of pyramidal neurons, i.e., the basket 
and chandelier cells, is crucial to seizure onset (Ribak et al., 1978, Ribak et al., 1979, 
Sloper et al., 1980, Sloviter, 1987, DeFelipe, 1999), but that the reduction of GABA 
transport and GAT expression may represent a compensatory response to homeostatically 
modulate neuronal overexcitation (Soudijn and van Wijngaarden, 2000). Moreover, 
reduced GAT expression in epileptic tissue may exacerbate epileptiform activity by 
decreasing the scope of GABA heterotransport (During et al., 1995, Gaspary et al., 1998, 
Patrylo et al., 2001).   
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A challenge in studies of resected human epileptogenic tissue is to obtain appropriate 
controls. The study of human MTLE hippocampal formation included in this thesis is 
based on surgically resected material from patients with epilepsy with a similarly resected 
MaTLE and PTLE hippocampal formation as controls. This control tissue is superior to 
autopsy material because the control tissue has been resected in the same manner as the 
tissue from MTLE patients. Moreover, the control and MTLE tissues have been subjected 
to similar regimens of antiepileptic drugs and have suffered a comparable degree of 
seizure activity. It is important to control for these factors because each factor may cause 
structural and/or biochemical changes capable of interfering with the interpretation of 
results. Additionally, unlike autopsy tissue, the surgically resected control tissue has not 
been subjected to proteolysis or other changes typical of postmortem tissue (Beckstrøm et 
al., Tessler et al., 1999, Zhou et al., 2012). The use of human tissue for these studies was 
approved by the Human Investigative Committee at Yale University. 
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Patients with medically intractable TLE underwent phased presurgical evaluation at the 
Yale-New Haven Hospital; appropriate candidates underwent an anteromedial temporal 
lobectomy with hippocampectomy according to standard procedures (Spencer et al., 
1984). Informed consent from each patient and institutional approval were obtained for 
the use of tissue in this project. The surgically resected hippocampi were classified into 
two groups, namely, (1) mesial temporal lobe epilepsy (MTLE) and (2) non-MTLE, as 
described by Eid et al. (Eid et al., 2004). The MTLE hippocampus was characterized by 
pronounced neuronal loss (>50 %) and extensive astroglial proliferation that was most 
pronounced in the hippocampal subfields of the CA1, CA3, and hilus regions (Kim, 
2001). Reorganization of peptidergic neurons (neurons containing dynorphin, 
somatostatin, neuropeptide Y, and substance P) in the dentate gyrus were also seen (de 
Lanerolle et al., 1994). In contrast, the non-MTLE hippocampi were recognized by a 
modest (<25 %) neuronal loss throughout all hippocampal subfields, minimal astroglial 
proliferation, and no reorganization of peptidergic neurons in the dentate gyrus (Kim, 
2001). They were obtained from patients with a mass lesion in the temporal lobe outside 
the hippocampus (MaTLE) and those with no clear etiology, described previously as 
paradoxical temporal lobe epilepsy (PTLE) (de Lanerolle et al., 1997). 
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Immediately after surgical resection, two 5-mm-thick slices were cut from the mid-
portion of the hippocampus. One of the samples was immersed in a fixative containing 4 
% formaldehyde and 15 % (v/v) of a saturated picric acid solution in 0.1 M phosphate 
buffer (PB), pH 7.4, for 1 hour, followed by immersion in 5 % acrolein in PB for 3 hours. 
Thereafter, the tissue was rinsed and stored in PB at 4 °C. Fifty-micrometer-thick coronal 
sections were cut on a vibratome and processed for immunohistochemistry. The other 
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sample was rapidly frozen on dry ice, stored at –80 °C, and later used for Western blot 
analysis. 
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The mesial temporal lobe consists of the hippocampus, parahippocampal gyrus, 
entorhinal cortex, and amygdala. The hippocampus is commonly divided into the 
subiculum, Ammon’s horn, and dentate gyrus (Lorente de Nó, 1934). The Ammon’s horn 
is further subdivided into the CA1, CA2, and CA3 regions, while the dentate gyrus is 
subdivided into the hilus, granule cell layer, and molecular layer (Amaral and Witter, 
1989).  
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Peptides representing parts of the glutamate and GABA transporter amino acid residues 
in the sequence were used in the antibody production. Map-peptides were used for 
immunization without coupling to carrier proteins, while the other peptides were coupled 
to either KLH, rabbit serum albumin, or thyroglobulin with either glutaraldehyde (with or 
without reduction with sodium borohydride) or MBS, as described previously (Danbolt et 
al., 1998). Antigenicity profiles were calculated for rat GLT-1 and EAAT3 according to 
Jameson and Wolf (Jameson and Wolf, 1988) using the Protean program (DNASTAR, 
Inc., Madison, WI, USA). The animals were immunized with peptides and bled as 
described previously (Danbolt et al., 1998). 
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In the first paper, antibodies against GAT1 (slc6a1) and GAT3 (slc6a11) were raised in 
rabbits and purified. The GAT1 antibodies were directed against amino acids 584-599 in 
the rat sequence (GPEQPQAGSSASKEAYI), which only differs by three amino acids in 
humans (GPEHAQAGSSTSKEAYI). The GAT3 antibody was raised against the C-
terminus (amino acids 607-677). Both antibodies showed high specificity in immunoblots 
of human hippocampal tissue.  
 
In Paper 2, antibodies against GLAST and GLT-1 were prepared by immunizing rabbits 
with synthetic peptides (A522-541 (PYQLIAQDNEPEKPVADSET) for GLAST and 
B563-573 (SVEEEPWKREK) for GLT-1) coupled to keyhole limpet hemocyanin with 
glutaraldehyde (Lehre et al., 1995, Danbolt et al., 1998). The corresponding anti-peptide 
antibodies are referred to as anti-A522 (rabbit 8D0161; Ab#314) and anti-B563 (rabbit 
1B0707; Ab#355). These antibodies were also tested and characterized by Western 
blotting and immunohistochemical methods and cross-reacted with human GLAST and 
GLT-1, respectively.  
 
Paper 4, which focuses on antibody specificity, showed that antibodies against the 
peptides could be isolated from the antisera in most cases, albeit in highly variable 
amounts (0-300 μg/ml serum). Testing of crude antisera was usually performed, but 
relevant antibodies were affinity-purified, as described previously, on columns containing 
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covalently immobilized antigen (Lehre et al., 1995, Danbolt et al., 1998). Sera from 
rabbits immunized with multiple peptides were passed through one affinity column for 
each of the peptides used for immunization. This procedure resulted in different antibody 
fractions, which were named according to the antigen immobilized on the respective 
affinity column. In this paper, the antiserum derived from rabbits was subjected to a four-
stage purification process, which included absorption against tubulin. Purified antibodies 
were spectrophotometrically quantified at 280 nm using bovine IgG as the standard. 
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ELISA, or enzyme-linked immunosorbent assay is a common laboratory technique that 
we used to test antibody specificity. In the ELISA procedure the separation of specific 
and non-specific interactions occurs via serial binding to a solid surface, usually a 
polystyrene multiwell plate (microtiterplate). The steps of the ELISA usually result in a 
colored end product which correlates to the amount of antigen present in the original 
sample, but we were, on the other hand, interested to see if the antibody binds to the 
antigen or not. ELISAs are quick and simple to carry out and, because it was performed 
by a pipetting robot (Tecan Genesis 200 Workstation), it was possible to test multiple 
antibodies simultaneously. The microtiterplates were coated with a known amount of 
antigen and antibodies were tested in different concentrations. Briefely; each well in the 
96-well microtiterplate was first incubated (2 hours) with 50 μl TBS (10 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 0.05 % NaN3) containing 3 μg antigen per ml and then washed 
with TBS (4 cycles, 50 s) to remove unbound antigen. To block free binding sites, the 
wells were incubated with TBS (380 μl/well) containing 20 % NCS for 2 hours with 
agitation and washed in TBS with 0.05 % (v/v) Tween 20 (TBST) (4 cycles, 50 s). 
Antibody fractions to be tested were diluted in blocking solution to the desired 
concentration. A 50-μl sample was added to each well, incubated for 60 min, and washed 
with TBST (8 cycles, 50 s). The wells were incubated for 60 min with 50 μl of TBST 
containing 20 % NCS and alkaline phosphatase-conjugated anti-rabbit diluted 1:1000. A 
final washing with TBST (8 cycles, 50 s) was followed by the addition of 100 μl of p-
nitrophenyl phosphate (1 mg/ml) in 0.1 M diethanolamine-HCl buffer (pH 9.8) with 1 
mM MgCl2. The OD405 was measured after 60 min. Background levels in each assay 
were determined using BSA as the coating antigen. 
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Immunohistochemistry refers to a technique where you the detect antigens, in our case 
transporter proteins, in tissue sections by exploiting the principle of antibodies binding 
specifically to the antigens of interest. Immunohistochemisty followed by microscopy 
was useful for studying the transporter protein’s localization at the regional, cellular, and 
subcellular levels. Vibratome sections in human hippocampal tissue were blocked and 
incubated free-floating in anti-A522 (200 ng/ml) or anti-B563 (200 ng/ml) antibodies for 
24 hours (RT), and they were then processed according to the avidin-biotin peroxidase 
method (Hsu et al., 1981) using a commercially available kit (Vectastain Elite, Vector 
Laboratories, Burlingame, CA). The immunoreagents diffused into the sections from the 
surface, and the sections from each patient were mounted on slides, dehydrated, and 
cover-slipped for light microscopy analysis. Control sections incubated without the 
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primary antibody or by replacing the primary antibody with preimmune sera were not 
immunostained.  
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An electron microscope (EM) is a microscope that utilize the same principles as an 
optical microscope, but rather than visible light, uses accelerated electrons as a source of 
illumination. Because the wavelength of an electron is much shorter than that of visible 
light photons, the electron microscope has a higher resolving power than a light 
microscope and can reveal the structure of smaller objects. Electron microscopes are used 
to investigate the ultrastructure of a wide range of specimens and we used EM to evaluate 
transporter protein in relation to cell types and cellular structures. All electron 
microscopy samples were prepared by labeling and resin embedding before placed in the 
microscope vacuum. After immunostaining as described above, 45-70 nm thin sections 
were treated with 2 % osmium tetroxide in PB, stained en bloc with 2 % uranyl acetate in 
water, dehydrated, and flat-embedded in a plastic resin (Durcupan ACM). Sections were 
cut on an ultramicrotome, transferred to 500-mesh copper grids (Electron Microscopic 
Sciences, Fort Washington, PA, USA), contrast-stained with lead citrate, and examined 
by a transmission electron microscope [Jeol 1200 EX II] at 60 kV.  
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Western blotting is a widely used analytical technique used to detect specific proteins in a 
sample of tissue homogenate or extract. The first step in a Western blotting procedure is 
to separate the tissue proteins by their size using gel electrophoresis and then transfer the 
proteins onto a nitrocellulose or polyvinylidene difluoride (PVDF) membrane. Next, the 
membrane is blocked to prevent any nonspecific binding of antibodies to the surface of 
the membrane and the transferred protein of interest is complexed with an enzyme-
labeled antibody as a probe. An appropriate substrate is then added to the enzyme and 
together they produce a detectable product (e.g. colorimetric detection). Proteins in a 
tissue homogenate from human hippocampi were separated by molecular weight by SDS-
PAGE (Laemmli, 1970) and subsequently transferred from the gel to a membrane 
(Towbin et al., 1979). The proteins on the nitrocellulose membranes were immunolabeled 
with the antibodies specific for the glutamate and GABA transporters. Secondary 
antibodies conjugated to alkaline phosphatase or horseradish peroxidase enabled 
visualization of probed antigens, and the immunocomplexes were detected by 
chemoluminescence, which is a very sensitive method. A standard curve was created with 
increasing concentrations of homogenized hippocampal tissue from a non-MTLE patient 
to determine the linear range. A CCD camera captured the chemoluminescence signals. 
We used a Kodak camera, which converts optical brightness into electrical amplitude 
using a charge-coupled device (CCD). The signals were converted to digital values using 
Kodak software. The CCD camera we used from Kodak provided a digital recording after 
very short exposure times. Both antibodies yielded a strong, single band consistent with 
the expected molecular mass of the glial glutamate transporters. Substitution of the 
primary antibodies with normal serum completely abolished the staining. The blots were 
assessed using a two-tailed Mann-Whitney U test (Statview Software, SAS Institute, 
NC).  
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All animal experimentations were carried out in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC). Formal approval to 
conduct the experiments described was obtained from the Animal Subjects Review Board 
of the Norwegian Governmental Institute of Public Health (Oslo, Norway). Care was 
taken to minimize the number of animals used and to avoid suffering. Mice were housed 
and bred as described previously (Zhou et al., 2012). Mice lacking GLT-1 were originally 
generated by Tanaka (Tanaka et al., 1997), and the breeding of heterozygous mice in a 
C57Bl/6 background produced the knockout and wild-type mice. All experiments were 
performed using the wild-type and knockout littermate pairs to maximize the probability 
that differences between wild-type and knockout mice were due to GLT-1 and not to 
other factors, such as age or rearing conditions. Because the GLT-1 knockout mice 
tended to die prematurely (Tanaka et al., 1997), the mice used were approximately 3 
weeks old. At this age, GLT-1 and GLAST expression levels are approximately half of 
the adult levels (Ullensvang et al., 1997, Diamond, 2005).  
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In Paper 3, five GLT-1 knockout and seven wild-type mice were administered an 
intraperitoneal injection with 70-150 μl of 0.3 M [1-13C]glucose (543 mg/kg) plus 0.6 M 
[1,2-13C]acetate (504 mg/kg). Fifteen minutes later, the mice were decapitated, and their 
heads were immediately frozen in liquid nitrogen and stored at -80 °C. The tissue 
samples were subjected to a water/methanol-chloroform extraction method as previously 
described (Le Belle et al., 2002). Samples were homogenized in 300 µl of methanol using 
a Vibra Cell™ sonicator (Model VCX 750, Sonics & Materials, Newtown, CT, USA), 
and α-ABA was used as an internal standard for HPLC analysis. After extraction, 
samples were lyophilized and re-suspended in 200 µl of deuterium oxide (D2O); 10 µl 
was removed for HPLC analysis, and the rest was lyophilized and re-dissolved in 120 µl 
of D2O containing 0.2908 g/l TSP and 0.1 % ethylene glycol as internal standards for 
quantification in 13C and 1H NMR analysis.  
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The samples were analyzed using a Hewlett Packard 1100 System (Agilent Technologies, 
Palo Alto, CA, USA) with fluorescence detection after derivatization with o-
phtaldialdehyde (Geddes and Wood). The amino acid components were separated with a 
ZORBAX SB-C18 (4.6 × 150 mm, 3.55 µm) column from Agilent using 50 mM sodium 
phosphate buffer (pH 5.9) with 2.5 % tetrahydrofurane plus methanol (98.75 %) and 
tetrahydrofurane (1.25 %) as eluents.  
 
+-+#!""#!"'
Nuclear magnetic resonance (NMR) is better known as magnetic resonance imaging 
(MRI) or magnetic resonance spectroscopy (MRS) in clinical practice. The main 
principle of NMR is based on the fact that nuclei with an uneven mass number and/or an 
odd number of protons, such as 1H and 13C, have magnetic properties (nuclear spin).  
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In 13C magnetic resonance spectroscopy (13C MRS) experiments with a 13C-labeled 
substrate, one exploits the fact that most carbon atoms are 12C (without a magnetic 
moment) and only 1.1 % are 13C (with a magnetic moment). Thus, by in vivo 
administration of 13C-labeled substrates such as [1-13C]glucose and 1,2-13C]acetate used 
in this thesis, followed by 13C and 1H MRS of brain extracts, the incorporation and exact 
position of 13C in important metabolites can be detected. Specific peaks in the spectra that 
are produced represent different compounds in the sample. The amount of 13C in different 
metabolites is quantified from integrals of the relevant peaks in the spectra using ethylene 
glycol as an internal standard with a known amount of 13C. Furthermore, 13C MRS allows 
the study of metabolic interactions between different cellular compartments (Sonnewald 
and Kondziella, 2003). The spatial segregation of the enzymes PAG, GAD, and GS to 
different cell types causes the majority of glutamate, GABA, and glutamine to be 
synthesized in different compartments. The glutamatergic neurons contain the largest 
pool of glutamate, whereas GABAergic neurons hold the GABA pool (Storm-Mathisen et 
al., 1983, Ottersen and Storm-Mathisen, 1985). Both types of neurons contain PAG 
(Kvamme et al., 1988), whereas only astrocytes contain GS (Martinez-Hernandez et al., 
1977). The interpretation of the MRS data is further based on the knowledge of the 
metabolic fate of [1-13C]glucose and [1,2-13C]acetate in neurons and astrocytes. Glucose 
is taken up into both neurons and astrocytes, but it is metabolized to a greater extent in 
neurons (Qu et al., 2000b). However, acetate is almost exclusively metabolized in 
astrocytes (Hassel and Sonnewald, 1995a, Waniewski and Martin, 1998). Thus, 
administrating both [1-13C]glucose and [1,2-13C]acetate to animals enables a more 
detailed metabolic analysis of the different cellular compartments.  
 
Analysis of all samples in Paper 3 was performed using a QCI CryoProbe™ 600-MHz 
ultrashielded Plus magnet (Bruker BioSpin GmbH, Reinstetten, Germany). 1H NMR 
spectroscopy was employed to quantify the amount of amino acids and lactate in extracts 
from the frontal cortex and cerebellum of wild-type and GLT-1 KO mice. 1H NMR 
spectra were acquired using a pulse angle of 90°, a 12-kHz spectral width and derived 
from 66 data points, an acquisition time of 2.66 s, a relaxation delay of 10 s, and 128 
scans. Proton-decoupled 13C MR spectra were obtained on the same instrument using a 
30° pulse angle, a 30-kHz spectral width derived from 98,000 data points, an acquisition 
time of 1.65 s, and a relaxation delay of 0.5 s. The number of scans needed to obtain an 
appropriate signal-to-noise ratio was 10,000. TopSpin™ 3.0 software (Bruker BioSpin 
GmbH, Reinstetten, Germany) was used for the acquisition, integration, and 
quantification of data. 
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Figure 4.  
Schematic presentation of glial interactions with glutamatergic and GABAergic neurons following the 
uptake of [1,2-13C]acetate. [1,2-13C]acetate is preferentially metabolized in astrocytes and enters astrocytic 
TCA (Kreb’s cycle) as [1,2-13C]acetyl CoA. [4,5-13C]α-ketoglutarate may leave the astrocytic TCA cycle as 
[4,5-13C]glutamate, which can then be transformed to [4,5-13C]glutamine by the action of the astrocyte-
specific enzyme glutamine synthetase. [4,5-13C]glutamine then leaves astrocytes via glutamine transporters 
(SNAT3) into the extracellular compartment from where it is taken up by neurons (SNAT1 in GABAergic 
neurons and SNAT2 in glutamatergic neurons). [4,5-13C]glutamine may be oxidized as an energy source or 
alternately deamidated to [4,5-13C]glutamate by the action of phosphate-activated glutaminase; it may also 
be a substrate of glutamate decarboxylate (GAD) in the formation of [1,2-13C]GABA in neuronal cell 
bodies. To date, glutamine transporters have not been directly identified in glutamatergic terminals. 
Abbreviations: GAD: glutamate dehydrogenase; Glu: glutamate; Gln: glutamine; GS: glutamine synthetase; 
PAG: phosphate-activated glutaminase. (Bjørnsen et al., 2014) 
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To understand the labeling pattern of metabolites after the administration of the labeled 
substrates [1-13C]glucose and [1,2-13C]acetate, it is necessary to consider their major 
biochemical pathways. Glucose is taken up and utilized by both neurons and astrocytes; 
however, 66 % of acetylCoA produced from glucose in the brain enters the neuronal 
tricarboxylic acid cycle (TCA) (Hassel and Sonnewald, 1995a, Qu et al., 2000a). 
Following uptake, [1-13C]glucose enters glycolysis, which results in the formation of one 
molecule of [3-13C]pyruvate and one molecule of unlabeled pyruvate. [3-13C]pyruvate 
can be converted to [3-13C]lactate or [3-13C]alanine in the cytosol or enter the 
mitochondria and be converted to [2-13C]acetylCoA. [2-13C]acetylCoA condenses with 
oxaloacetate to form the TCA cycle intermediates [2-13C]citrate and [4-13C]α-
ketoglutarate. The 13C label can exit the TCA cycle in the form of [4-13C]α-ketoglutarate, 
which can be converted to [4-13C]glutamate or alternately continue in the cycle. The [4-
13C]glutamate, which is either taken up by astrocytes or made by astrocytes, can be 
converted to [4-13C]glutamine by the enzyme glutamine synthetase (GS), or it can enter 
the TCA cycle in astrocytes after conversion to [4-13C]α-ketoglutarate to ultimately form 
[3 or 2-13C]glutamine. Any glutamine taken up by neurons may be converted back to 
glutamate by phosphate-activated glutaminase (PAG) in the mitochondria. However, if 
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the 13C label from [1-13C]glucose remains in the TCA cycle for a second round, equal 
amounts of 13C will be incorporated into the 2 or 3 positions of glutamate and glutamine 
(Melo et al., 2006). Unlike glucose, acetate is taken up only by astrocytes (Waniewski 
and Martin, 1998). After uptake by astrocytes, [1,2-13C]acetate is converted to [1,2-
13C]acetylCoA, which then condenses with oxaloacetate to form TCA cycle 
intermediates. [4,5-13C]α-ketoglutarate can be converted to [4,5-13C]glutamate, which is 
rapidly converted to [4,5-13C]glutamine by the astrocytic GS. Glutamine can then be 
transported to neurons and converted back to [4,5-13C]glutamate via phosphate-activated 
glutaminase.  
 
Relevant peaks in the spectra were assigned and quantified from the integrals of the peaks 
using ethylene glycol as an internal standard with known amounts of 13C. Corrections for 
natural abundance as well as nuclear Overhauser enhancement and relaxation effects 
relative to the internal standard were applied to all relevant integrals from 13C spectra.  
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Student’s t-tests were used, and p < 0.05 was regarded as significant.  
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“GAT1 and GAT3 expression are differently localized in the human epileptogenic 
hippocampus” 
 
!$
The involvement of GABA in TLE is controversial and the distribution of GABA 
transporters in the human hippocampus has been described in only two other studies 
(Mathern et al., 1999, Arellano et al., 2004b). It has been hypothesized that the 
diminished GABA release is caused by a reduction of GABA transporters (During et al., 
1995), although no direct measurements of GABA transporters in the human 
hippocampus have been performed. Previous studies have only studied immunoreactivity 
on tissue sections, so we used immunohistochemistry and immunoblots. In this paper, we 
evaluated whether the low levels of glutamate-induced extracellular GABA in the 
epileptogenic hippocampus (During and Spencer, 1993) were related to changes in the 
expression of the GABA transporters GAT1 and GAT3.  
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The GABA transporters were localized by immunohistochemistry in hippocampi 
removed from patients with medically intractable TLE. The antibodies specificity were 
tested on immunoblots, but not checked against knockout tissue. The GAT3 showed an 
additional single narrow band with molecular weight lower than expected for the 
transporter protein. GAT1 was localized in axon terminals and small neuronal cell bodies 
and showed reduced immunoreactivity in the dentate granule cells, CA1 and CA3 regions 
of the epileptogenic hippocampus. GAT3 was weakly expressed on astrocytes in non-
sclerotic hippocampi, but was more prominently expressed in sclerotic hippocampi. 
GAT3 expression was confined to cells resembling protoplasmic astrocytes, which were 
located in regions of relative neuronal sparing, such as the dentate gyrus and hilus of the 
sclerotic hippocampus. Despite these changes in immunoreactivity, Western blot analysis 
showed no significant difference in GAT1 or GAT3 levels between the two groups.  
However, immunohistochemical staining showed regional differences in GAT1 
immunoreactivity within the hippocampus.  

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Taken together with Western blot data, these findings may reflect a compensatory up-
regulation and may account for the lack of the difference between sclerotic and non-
sclerotic hippocampi in the immunoblots. It may be inferred from this paper that rather 
than an overall decrease in GABA transporters, there is, at best, no overall change. 
Theoretically, the local GAT1 reductions found in our study may have caused regional 
increases in the excitability of neurons, e.g., the dentate granule cells, because of the loss 
of inhibition normally associated with GABA release from GAT1-bearing terminals. The 
increase in GAT3 astrocytes in TLE may also contribute to the excitable state by excess 
removal of GABA from the extracellular space. It should be noted that the antibodies 
specificity were not tested on knockout mice.   
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 “Changes in glial glutamate transporters in human epileptogenic hippocampus: 
inadequate explanation for high extracellular glutamate during seizures” 

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Elevated levels of extracellular glutamate have been observed in patients with various 
epilepsies (Janjua et al., 1992, Ferrie et al., 1999) and have also been reported to be 
elevated in epileptogenic hippocampi. Glutamate is thought to play a major role in the 
initiation and spread of seizure activity (Meldrum, 1994) and intracellular recordings 
from human MTLE hippocampi reveal a glutamate-dependent hyperexcitability 
(Williamson and Spencer, 1994). Previous studies of the distribution of GLAST and 
GLT-1 in surgically removed human sclerotic hippocampi compared with that in non-
sclerotic hippocampi concluded that there is a reduction in GLT-1 (Mathern et al., 1999, 
Proper et al., 2002), a slight or no reduction in GLAST (Mathern et al., 1999), or 
essentially no change in these transporters (Tessler et al., 1999). The aim of this study 
was to further explore the differences in glial transporter distribution in the non-sclerotic 
(non-MTLE) and sclerotic (MTLE) hippocampi of TLE patients.  
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Western blotting was performed on human tissue that was obtain from the OR. There 
were no overall significant difference in the expression in transporters GLAST and GLT-
1 between the non-MTLE and MTLE hippocampi, but the pattern of immunolabeling 
were different.  
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The previous reports of reduced astrocyte glutamate transporters in the sclerotic 
hippocampi from patients with TLE are not compelling, but our findings are consistent 
with Tessler and colleagues (Tessler et al., 1999). Our study used other antibodies than 
the studies that found a downregulation of GLT-1 and GLAST (Mathern et al., 1999, 
Proper et al., 2002), which could explain the discrepancies. Both the use of fixatives 
(Danbolt, 2001) and postmortem autolytic changes (Beckstrøm et al., 1999) may also 
cause different results. We found it difficult to explain the reduced immunoreactivity in 
areas such as the CA1 and hilus regions in sclerotic hippocampi, while immunoblot 
analyses showed no overall difference. Our result may reflect redistribution of the 
transporter proteins throughout the astrocytic processes in the sclerotic hippocampi, 
rather than a true reduction in level. Ultrastructural localization studies show GLT-1 
immunoreactivity throughout the astrocytic process despite the apparent loss suggested 
by light microscopy analysis. Likewise, confocal immunohistochemical studies reveal 
GLT-1 immunoreactivity throughout astrocyte processes, even though staining in somata 
is reduced (Eid et al., 2004). An alternative possibility is that there may be compensatory 
changes in the expression of transporters in different regions of the hippocampus. We 
found little support for glutamate transporters as the direct cause of elevated levels of 
extracellular glutamate in the epileptogenic hippocampi. Our study cannot exclude the 
possibility that there may be small changes in transporters, such as splice variants, which 
are not distinguished by the antibodies used in this study.  
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“The GLT-1 (EAAT2; slc1a2) glutamate transporter is essential for glutamate 
homeostasis in the neocortex of the mouse” 

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Based on the reported correlation between glutamate transporter dysfunction and epilepsy 
in mutant mice lacking GLT-1 (Tanaka et al., 1997), we wanted to evaluate the role of 
GLT-1 in glutamate homeostasis. Knockout mice have increased extracellular glutamate 
levels and developed spontaneous seizures. We know that there is no glutamate uptake 
activity in hippocampal terminals in GLT-1 knockout mice and our aims were to analyze 
if the distribution of metabolic substrate between the cellular compartments would be 
different in these animals.  
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Using 13C magnetic resonance spectroscopy (MRS) of cortical tissue from mice lacking 
the glutamate transporter GLT-1 (EAAT2; slc1a2) was performed following an 
intraperitoneal injection of 13C-labeled glucose and acetate. GLT-1 is expressed at the 
highest levels in the forebrain (Lehre et al., 1995), and the deletion of the GLT-1 gene 
causes a reduction in glutamate uptake activity by approximately 95 % (Tanaka et al., 
1997, Otis and Kavanaugh, Matsugami et al., 2006, Furness et al., 2008, Kiryk et al., 
2008, Holmseth et al., 2009). Metabolite levels were analyzed in extracts from the 
neocortex and cerebellum and by 13C labeling in the neocortex. Compared with wild-type 
mice, GLT-1 knockout mice had normal levels of glutamate and glutamine in the 
cerebellum, but decreased levels in the neocortex. However, 13C-labeled glutamate 
showed no significant difference in the neocortex, even though a trend was visible. In 
contrast, a reduction in 13C-labeled glutamine in the GLT-1 knockout mice was present. It 
is believed that the TCA cycle metabolism of [1-13C]glucose-derived metabolites 
primarily reflects neuronal energy metabolism (Hassel et al., 1995, Qu et al., 2000a). The 
contribution of pyruvate carboxylation toward the labeling of these metabolites was 
unchanged between the wild-type and GLT-1 knockout mice. Labeling from [1,2-
13C]acetate was decreased in glutamate and glutamine, indicating reduced mitochondrial 
metabolism in the astrocytes.  
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These findings suggest that GLT-1 in nerve terminals in the cerebral cortex may 
significantly contribute to the replenishment of the pool of glutamate transmitter. Thus, 
the efficiency of the glutamate-glutamine cycle in the replenishment of the glutamate 
neurotransmitter pool needs reconsideration. Based on the fact that the knockout mice 
survive the first month of life (Tanaka et al., 1997), it is possible that other glutamate 
transporters, to a certain degree, are able to prevent initial accumulation of glutamate 
extracellularly. Our study is not able to determine if other factors, e.g. changes in receptor 
expression or function, play an important role in neurotoxic protection. We will neither 
be able to measure the concentration of metabolites in the different intra- and 
extracellular compartments.   
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“Specificity of antibodies: Unexpected cross-reactivity of antibodies directed against the 
excitatory amino acid transporter 3 (EAAC1) glutamate transporter” 
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Initially, the aim of this study was to quantify and localize EAAT3 to gain insight into its 
physiological functions and localization. Our group had seen a mismatch between 
western blotting and labeling of tissue sections when using our EAAT3 antibodies. Data 
in the literature claimed that EAAT3 was responsible for more than 30% of the total 
glutamate uptake activity (Rothstein et al., 1996) and we wondered whether this result 
was correct. Another study supported this belief by Kugler and Schmitt showed strong 
labeling with colocalization of EAAT3 and tubulin (Kugler and Schmitt, 1999).  
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During the development of antibodies against the similar peptide (C480-499) that was 
used by Kugler and Schmitt, we found that there was cross-reactivity with tubulin despite 
an absence of primary sequence similarly with EAAT3. This observation made us 
question if the previous studies had used antibodies that recognized multiple proteins. 
The majority of the antibodies we generated against different peptides did not recognize 
the native protein, but antibodies raised against the C-terminus of the EAAT3 protein 
molecule gave rise to weak labeling in Western blots, but remarkably strong labeling in 
tissue sections. I programed a robotic ELISA-system, which was used to screen 
antibodies’ reactivity toward a number of non-EAAT3 proteins. The antibodies reacted 
strongly with tubulin and did so with a remarkable specificity. The antiserum was then 
fractionated. We obtained one fraction that recognized both tubulin and EAAT3 and 
another fraction that appeared specific for EAAT3. The EAAT3-specific fraction did not 
label axons. The labeling appeared restricted to the dendrosomatic compartment and there 
was no labeling of oligodendrocytes or astroglia.  
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Determination of the antibody specificity is not straightforward and might give 
unexpected results. EAAT3 was thought to be localized in oligodendrocytes, because of 
the cross-reactivity between EAAT3 and tubulin observed by Kugler and Schmitt. We 
made similar antibodies that recognized a strong band that did not correspond to the 
glutamate transporter. Initially, it was thought that this band could represent a novel and 
much more abundant variant of EAAT3, but it was eventually found, after extensive 
testing using a robotic ELISA procedure, to correspond to tubulin. This work shows that 
the cross-reaction with apparently completely unrelated proteins is very common and, 
importantly, this study also suggests that the pre-adsorption test has little value when 
testing affinity-purified antibodies. Optimally all antibodies should be tested on knockout 
tissue to verify specificity.  
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